<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289545</url>
  </required_header>
  <id_info>
    <org_study_id>11367/2019</org_study_id>
    <nct_id>NCT04289545</nct_id>
  </id_info>
  <brief_title>Postprandial Effects of Functional Bread</brief_title>
  <official_title>Postprandial Effects of Functional Bread</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether bread with added galactomannan, a soluble fiber, can reduce
      the postprandial glucose response in healthy overweight adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-blind crossover-designed study wants to investigate the postprandial effect of
      functional bread in healthy overweight adults. Therefore, four types of bread, consumed by
      the participants, have added galactomannan in different amounts and viscosities, and one
      bread is the control bread.

      The participants arrive after an overnight fast and before the consumption of bread, a
      fasting blood sample is taken.

      After the ingestion, blood samples are taken at specific times. The area under the curve of
      the postprandial glucose is expected to differ between the functional breads.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the curve of postprandial glucose</measure>
    <time_frame>180 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>area under the curve postprandial insulin</measure>
    <time_frame>180 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Postprandial Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Control Bread</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no added guar gum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functional Bread 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10% guar gum, low molecular weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>functional Bread 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10% guar gum, high molecular weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functional Bread 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15% guar gum, low molecular weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functional Bread 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15% guar gum, high molecular weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Functional bread</intervention_name>
    <description>Postprandial effects of bread containing galactomannan</description>
    <arm_group_label>Control Bread</arm_group_label>
    <arm_group_label>Functional Bread 1</arm_group_label>
    <arm_group_label>Functional Bread 3</arm_group_label>
    <arm_group_label>Functional Bread 4</arm_group_label>
    <arm_group_label>functional Bread 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy, overweight adults (BMI between 25 and 30 kg/m2)

        Exclusion Criteria:

          -  Known diagnosis of diabetes mellitus type 2

          -  HbA1c at screening ≥ 48 mmol/mol

          -  Other chronic diseases (heart disease, cancer) within the last 3 years

          -  Pregnancy and lactation

          -  Known drug or alcohol abuse

          -  Unwilling to follow the study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta Dierkes, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jutta Dierkes, PhD</last_name>
    <phone>004755977344</phone>
    <email>jutta.dierkes@uib.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gülen A Lied, PhD</last_name>
    <email>gulen.arslan@uib.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bergen, Research Unit for Health Surveys</name>
      <address>
        <city>Bergen</city>
        <zip>5020</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Gomez Real, PhD</last_name>
      <phone>+47 55 58 00 00</phone>
      <email>Francisco.Real@uib.no</email>
    </contact>
    <contact_backup>
      <last_name>Jutta Dierkes, PhD</last_name>
      <phone>+4755977344</phone>
      <email>jutta.dierkes@uib.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

